NCT04047953
Recruiting
Not Applicable
The Study of Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Initial Unresectable Local Advanced or Potentially Resectable Metastatic Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute1 site in 1 country95 target enrollmentStarted: September 10, 2019Last updated:
ConditionsGastric Adenocarcinoma
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Enrollment
- 95
- Locations
- 1
- Primary Endpoint
- R0 resection rate
Overview
Brief Summary
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age of 18-75 years; male or female.
- •Karnofsky Performance Status Score ≥
- •Histological diagnosis of gastric adenocarcinoma, HER2 expression negative.
- •The initial unresectable locally advanced or potentially resectable metastatic gastric adenocarcinoma, potentially resectable factor includes a single liver metastases, localized abdominal para-aortic lymph node (16a1 / b2) metastasis or positive abdominal free cancer cells.
- •Physical condition and organ function allow for larger abdominal surgery.
- •Subject baseline blood routine and blood biochemistry indexes meet the following criteria: hemoglobin(HB) ≥90 g/L; absolute neutrophil count(ANC) ≥1.5×109 /L; platelet count(PLT) ≥100×109 /L; alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN); total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN); Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); Serum albumin≥30g/L.
- •Echocardiographic scan confirmed left ventricular ejection fraction (LVEF) ≥ 50%.
- •No serious accompanying disease lead to a survival period of \<5 years.
- •Agree and be able to follow the protocol during the study period.
- •Written informed consent was provided prior to the study screening and the patient was informed that the study could be withdrawn at any time during the study without any loss.
Exclusion Criteria
- •For the treatment of the gastric cancer, patients who have received cytotoxic chemotherapy, radiotherapy or immunotherapy, except corticosteroids.
- •Pregnancy or breastfeeding woman.
- •Women of childbearing age who had a positive pregnancy test at baseline or who did not undergo a pregnancy test. Menopausal women must be stopped for at least 12 months to ensure that no pregnancy is possible.
- •Men and women who have sex (with fertility probability) are reluctant to contraception during the study.
- •Patients with ascites and positive abdominal free cancer cells.
- •There are other history of malignant disease in the last 5 years, except for cured skin cancer and cervical carcinoma in situ.
- •Those with a history of epilepsy, central nervous system disease, or mental disorder may be judged by the investigator that their clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.
- •Clinically severe (active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe drug-affected arrhythmias, or there is a history of myocardial infarction in the last 12 months.
- •Upper gastrointestinal stagnation or abnormal physiological function or malabsorption syndrome may affect the absorption of S-
- •It is known to have peripheral neuropathy ≥ NCI CTC AE grade
Arms & Interventions
Conversion Therapy
Experimental
Paclitaxel (albumin-bound) +S-1+Oxaliplatin
Intervention: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 (Drug)
Outcomes
Primary Outcomes
R0 resection rate
Time Frame: within 4 weeks following the operation
Proportion of patients who achieved R0 resection
Secondary Outcomes
- overall survival (OS)(5 years)
- Adverse Events(AEs)(until 28 days after the last study drug administration)
- Progression free survival (PFS)(5 years)
Investigators
Zhaode Bu
Clinical Professor
Peking University Cancer Hospital & Institute
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical CancerCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell CarcinomaRecurrent Cervical CarcinomaStage IVA Cervical CancerStage IVB Cervical CancerNCT00057863National Cancer Institute (NCI)35
Recruiting
Phase 2
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaGastric/Gastroesophageal Junction AdenocarcinomaNCT06415669The First Affiliated Hospital of Xiamen University30
Completed
Phase 2
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to CisplatinNeoplasms, Germ Cell and EmbryonalNCT00611962Sanofi27
Not yet recruiting
Phase 1
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric AdenocarcinomaGastric CarcinomaNCT03599778Anhui Provincial Hospital52
Unknown
Phase 2
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st ChemotherapySmall Cell Lung CancerNCT04698941Shanghai Pulmonary Hospital, Shanghai, China40